scholarly journals Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?

Endocrine ◽  
2012 ◽  
Vol 42 (1) ◽  
pp. 3-4 ◽  
Author(s):  
Kjell Öberg
Keyword(s):  
Neuroendocrine Tumors ◽  
Somatostatin Receptor ◽  
Pet Ct ◽  
Gallium 68

scholarly journals Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Sowon Oh ◽  
Vikas Prasad ◽  
Dong Soo Lee ◽  
R. P. Baum
Keyword(s):  
Glucose Metabolism ◽  
Neuroendocrine Tumors ◽  
Fdg Pet ◽  
Radionuclide Therapy ◽  
Somatostatin Receptor ◽  
Peptide Receptor Radionuclide Therapy ◽  
Receptor Expression ◽  
Peptide Receptor ◽  
Pet Ct ◽  
Fdg Pet Ct

The heterogeneous nature of the neuroendocrine tumors (NET) makes it challenging to find one uniformly applicable management protocol which is especially true for diagnosis. The discovery of the overexpression of somatostatin receptors (SMS-R) on neuroendocrine tumor cells lead to the generalized and rapid acceptance of radiolabeled somatostatin receptor analogs for staging and restaging of NET as well as for Peptide Receptor Radionuclide Therapy (PRRNT) using Y-90 and Lu-177 DOTATATE/DOTATOC. In this present work we tried to look in to the effect of PRRNT on the glucose metabolism assessed by F-18 FDG PET/CT and SMS-R density assessed by Ga-68 DOTANOC PET/CT. We observed a complex relationship between the somatostatin receptor expression and glucose metabolism with only 56% (77/138) of the lesions showing match, while the others show mismatch between the receptor status and metabolism. The match between receptor expression and glucose metabolism increases with the grade of NET. In grade 3 NET, there is a concurrence between the changes in glucose metabolism and somatostatin receptor expression. PRRNT was found to be more effective in lesions with higher receptor expression.

scholarly journals Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 8 ◽  
Author(s):  
Jiale Hou ◽  
Yi Yang ◽  
Na Chen ◽  
Dengming Chen ◽  
Shuo Hu
Keyword(s):  
Positron Emission Tomography ◽  
Neuroendocrine Tumors ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Somatostatin Receptor ◽  
Progression Free Survival ◽  
Emission Tomography ◽  
Cochrane Library ◽  
Positron Emission ◽  
Pet Ct

Purpose: A meta-analysis was conducted to investigate the value of the volume parameters based on somatostatin receptor (SSTR)-positron emission tomography (PET) in predicting the prognosis in patients with neuroendocrine tumors (NETs).Material: PUBMED, EMBASE, Cochrane library, and Web of Knowledge were searched from January 1990 to May 2021 for studies evaluating prognostic value of volume-based parameters of SSTR PET/CT in NETs. The terms used were “volume,” “positron emission tomography,” “neuroendocrine tumors,” and “somatostatin receptor.” Pooled hazard ratio (HR) values were calculated to assess the correlations between volumetric parameters, including total tumor volume (TTV) and total-lesion SSTR expression (TL-SSTR), with progression-free survival (PFS) and overall survival (OS). Heterogeneity and subgroup analysis were performed. Funnel plots, Begg's and Egger's test were used to assess possible underlying publication bias.Results: Eight eligible studies involving 593 patients were included in the meta-analysis. In TTV, the pooled HRs of its prognostic value of PFS and OS were 2.24 (95% CI: 1.73–2.89; P < 0.00001) and 3.54 (95% CI, 1.77–7.09; P = 0.0004), respectively. In TL-SSTR, the pooled HR of the predictive value was 1.61 (95% CI, 0.48–5.44, P = 0.44) for PFS.Conclusion: High TTV was associated with a worse prognosis for PFS and OS in with patients NETs. The TTV of SSTR PET is a potential objective prognosis predictor.

Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors

2019 ◽  
Vol 121 (3) ◽  
pp. 480-485 ◽  
Author(s):  
Angelena Crown ◽  
Flavio G. Rocha ◽  
Preethi Raghu ◽  
Bruce Lin ◽  
Gayle Funk ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Diagnosis And Management ◽  
Pet Ct ◽  
Initial Imaging ◽  
Gallium 68

Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study

2011 ◽  
Vol 197 (5) ◽  
pp. 1221-1228 ◽  
Author(s):  
Niraj Naswa ◽  
Punit Sharma ◽  
Abhishek Kumar ◽  
Aftab Hasan Nazar ◽  
Rakesh Kumar ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Single Center ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Pet Ct ◽  
Single Center Study ◽  
Gallium 68 ◽  
Center Study

scholarly journals Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT

2011 ◽  
Vol 11 (1) ◽  
pp. 179-183 ◽  
Author(s):  
Daniel Kaemmerer ◽  
Karl Khatib-Chahidi ◽  
Richard Paul Baum ◽  
Dieter Horsch ◽  
Norbert Presselt ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Pet Ct ◽  
Gallium 68
Sign in / Sign up

Export Citation Format

Share Document